[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alpha-1-antitrypsin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alpha-1-antitrypsin":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100603354","phase-4-genetic-variation-in-igg-in-alpha-1-antitrypsin-deficiency-100603354",false,"NCT07135427","Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency","Genetic Variation in IgG as a Mechanism for Immune Deficiency and Exacerbations in AATD","IgG in AATD","Inclusion Criteria:\n\n* Adults who are heterozygous for a SERPINA1 Z allele\n* Have either had no COPD exacerbations or 2 or more exacerbations in the previous year\n* Has not received a pneumococcal conjugate vaccine within the past 5 years, or has only received the pneumococcal polysaccharide vaccine in the past\n\nExclusion Criteria:\n\n* Received a pneumococcal conjugate vaccine within the past 5 years\n* Known allergy, severe adverse reaction, or other sensitivity to pneumococcal conjugate vaccines","ALL","19 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections.\n\nTo investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.",[27,28,29],"Alpha 1-Antitrypsin","COPD","Antibody Deficiency","RECRUITING","2025-11-05",{"date":33,"type":34},"2025-11-10","ACTUAL",{"date":36,"type":34},"2025-09-03",{"date":38,"type":21},"2027-06",{"name":40,"class":41},"University of Alabama at Birmingham","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100518361","permian-health-womens-lung-health-study-100518361","NCT06029543","Permian Health Women's Lung Health Study","WLHS","Inclusion criteria:\n\n* Self-identified female sex\n* Age \\> 15 years: This age cutoff was chosen (as opposed to 18) because of the unique cultural norms and practices in the country where experiences and exposures occur at an earlier age than women in Western countries.\n\nExclusion criteria:\n\n* Age \\\u003C 15 years\n* Non-resident household member\n* Any acutely unwell individual\n* Pregnancy\n* Any known history of active pulmonary disease (including TB) on treatment.\n* Individuals unable or unwilling to give consent.",true,"FEMALE","15 Years",{"count":54,"type":21},350,"3 Years","OBSERVATIONAL","The goal of this cross-sectional observational study is to estimate the prevalence of lung function impairment as measured by spirometry in a population of Gambian women aged 15 and older. The main question\\[s\\] it aims to answer are:\n\n* What is the prevalence of lung function impairment in Gambian women\n* What is the prevalence of eosinophilic inflammation in Gambian women\n\nConsenting participants will undergo\n\n* Spirometry\n* Fractional exhaled nitric oxide (FENO) testing\n* α1-antitrypsin testing in patients with lung function impairment as assessed by spirometry",[28,59,27],"Lung Function Decreased","NOT_YET_RECRUITING","2023-08-31",{"date":63,"type":34},"2023-09-08",{"date":65,"type":21},"2023-12",{"date":67,"type":21},"2026-12",{"name":69,"class":41},"Permian Health Lung Institute"]